NEW YORK (GenomeWeb News) – DxS said today that it plans to double the size of its Manchester, UK, manufacturing facility and to hire an undisclosed amount of new staff “over the coming months.”
The company said that the increase in capacity is the result of growing demand for its TheraScreen K-RAS assay, which determines patients’ K-RAS mutation status.
DxS said that the assay is the “preferred method” for K-RAS mutation screening for Amgen's Vectibix colorectal cancer therapy.
Stephen Little, CEO of DxS, said in a statement that sales of the K-RAS companion diagnostic for Vectibix “have increased radically over the last six months, necessitating an up-scaling in our manufacturing facilities.”
The company said that it has also been awarded the ISO 13485:2003 quality certification for the "design, development and manufacture of molecular diagnostic products for human genetic analysis.”